PROFESSOR C. H. ASHTON, DM,FRCP.
PAGE REFERENCES
Qualifications: I am Emeritus Professor of Clinical Psychopharmacology
and Consultant in Clinical Pharmacology, University of Newcastle Upon Tyne.
I ran a benzodiazepine withdrawal clinic at the Royal Victoria Infirmary,
Newcastle Upon Tyne, for twelve years from 1982 - 1994. During this time I
personally supervised withdrawal of these drugs from over three hundred
patients who were referred because they had problems with benzodiazepine
hypnotics and tranquillisers and wished to withdraw. During this time I became
closely acquainted with the difficulties experienced by these patients.
I have been a member of the executive committee of the North East Council on
Addictions for 10 years and its Vice Chairman since 1994. In this capacity I have
had contact with the problems of several hundreds of clients seeking advice and
support during benzodiazepine withdrawal and still provide regular advice for
clients with withdrawal and addiction/abuse problems.
As a result of publications in medical journals based on the above observations,
I receive at present correspondence and telephone calls at least weekly from
all over the UK and world-wide, from patients with benzodiazepine problems for
which they are unable to obtain adequate help. This level of concern from the
public makes it clear that the benzodiazepines still contribute a considerable
and unsolved health problem. The main issues are summarised below: BACK TO TOP
- Therapeutic dose dependence
It has been recognised since the early 1980s that benzodiazepine
tranquillisers and hypnotics can cause drug dependence when taken
long-term (for more than four weeks), even in prescribed
"therapeutic" doses(1,2).
PAGE REFERENCES
- Withdrawal Effects.
Because of widespread prescribing, a large number of UK patients
[estimated as about 1.2 million](3) become dependent on benzodiazepines.
Many had taken these drugs for 10 - 20 years, often in excessive, (though
prescribed) dosage. as a result a large proportion of these patients
suffered withdrawal symptoms (often severe) when they or their doctors
tried to withdraw or reduce dosage(4,5).
- Protracted withdrawal
effects:
It has become clear that benzodiazepine withdrawal symptoms may be
protracted, lasting months or years, in some 15% of long-term users(6). In
some cases chronic prescribed benzodiazepine use has resulted in
long-term, or possibly permanent disability(7,8,9).
- Continued long-term
prescribing:
Despite advice from the Committee on Safety of Medicines (10) and the
Royal College of Physicians(11) in 1988, that benzodiazepines should not
be prescribed for more than 2 - 4 weeks, there are still many long-term
prescribed users in the UK. Numbers of these are not known but a recent
survey indicates that there are 150-200 long-term users in every UK
general practice(12).
PAGE REFERENCES
5. Medical ignorance
about benzodiazepine withdrawal:
These patient often receive little support or advice from their doctors.
Medical practitioners in general are not well informed about benzodiazepine
withdrawal symptoms or methods of withdrawal(13). BACK TO TOP
- Paucity of advice and support
centres:
Scattered patient advice/self-help support groups exist in the UK but these
are few and inaccessible to many patients. Most are voluntary
organisations or charities, often without fully trained personnel. There
is little if any public funding specifically for patients with
benzodiazepine problems.
- Risks for the next generation.
Even longer-term benzodiazepine problems, affecting the next generation,
may now be emerging. It was recognised in the 1970s that benzodiazepines
taken by the mother during pregnancy (in prescribed doses) affect the
foetus and that the newborn of such mothers may suffer excessive sedation
and withdrawal effects(14). Public concern is now growing that
benzodiazepine exposure in utero may be associated with learning
difficulties, attention deficit disorder and other cognitive impairments
in children and adolescents. There have been no formal studies in this
area in the UK but animal work and clinical evidence fro Sweden is
strongly suggestive(15).
- Benzodiazepine abuse: Another serious consequence
of widespread benzodiazepine prescribing is the growing problem of
benzodiazepine abuse. especially among polydrug abusers(16,17).
Benzodiazepines (temazepam, diazepam and more recently flunitrazepam
[Rohypnol]) are taken illictly by around 50% of injecting drug users and
alcoholics. This type of benzodiazepine abuse usually involves very high
doses and sometimes intravenous injection. Benzodiazepines have become
widely available on the illicit market and the main sources are GP
prescriptions and thefts from retail chemists and drug warehouses.
BACK
TO TOP
PAGE REFERENCES
- Health risks of illicit use:
Health risks of abuse include, among others, risk-taking sexual behaviour,
foetal and neonatal risks in pregnancy, increased violence and criminal
behaviour, HIV and hepatitis B and C infection, and gangrene following
complications following injection(16,17).
- Health Committee Inquiry:
These concerns about benzodiazepines appear to merit an inquiry by the
Health Committee. Questions to be considered could include:
(a) - Should all benzodiazepines be moved to schedule 3 (like temazepam
and flunitrazepam) and should the prescribing requirements of the Misuse
of Drugs Regulations be introduced (at present exempted for temazepam)?
(b) - Should steps be taken to improve the education of medical
practitioners about benzodiazepine and related problems?
[note: some GPs are now prescribing Zopiclone or Zimovane instead of
benzodiazepines, in ignorance of the fact that these recently introduced
hypnotics/anxiolytics carry similar risks as benzodiazepines, both for
dependence and abuse](18).
(c) - Should government financial help be found for voluntary and charitable
organisations to provide advice and support for benzodiazepine withdrawal?
[Most GPs have neither the time nor expertise required for the lengthy
support needed by patients](13).
(d) - Should the government fund research into the long-term effects on
children who have been exposed to benzodiazepines in utero?
BACK TO TOP PAGE REFERENCES
Reproduced with kind permission from the
author.